Saturday, October 29, 2016
13:00 – 14:30
AUD I
FRONT-LINE OVARIAN CANCER: CAN WE DO BETTER? TODAY, TOMORROW
Symposium Organized by: ROCHE
Chair: Sandro Pignata (Italy)
13:00 DOING IT BETTER FROM THE BEGINNING
Sandro Pignata (Italy)
13:10 NEOADJUVANT TODAY AND TOMORROW: EXPERTS EXPERIENCE SHARING
Roman Rouzier (France)
13:25 DEBATE AT THE OPERATING TABLE
Sven Mahner (Germany) and Antonio Gonzalez Martin (Spain)
13:45 ADJUVANT THERAPY TODAY – WHAT'S NEW?
Nicoletta Colombo (Italy)
14:05 ADJUVANT THERAPY TOMORROW – WHAT'S NEXT?
Angeles Secord (USA)
14:25 WE CAN DO BETTER – TODAY AND TOMORROW
Sandro Pignata (Italy)
18:15 – 19:45
AUD I
THE ROLE OF IMMUNE CHECKPOINT INHIBITORS IN OVARIAN CANCER
Symposium Organized by: Merck-Pfizer
Chair: Jonathan Ledermann (United Kingdom)
18:15 WELCOME AND INTRODUCTION
Jonathan Ledermann (United Kingdom)
18:25 PRECLINICAL RATIONALE
Stéphanie Gaillard (USA)
18:45 CLINICAL DATA
Eric Pujade-Lauraine (France)
19:15 ONGOING TRIALS AND KEY CONSIDERATIONS FOR CLINICAL TRIAL DESIGN
Brad Monk (USA)
19:35 Q&A / CLOSING COMMENTS
Jonathan Ledermann (United Kingdom)
18:15 – 19:45
AUD VI + VII
TREATING OVARIAN CANCER: RIGHT PATIENT. RIGHT TREATMENT. RIGHT TIME.
Symposium Organized by: Astrazeneca
Chair: Nicoletta Colombo (Italy)
18:15 WELCOME AND INTRODUCTION
Nicoletta Colombo (Italy)
18:20 TREATING RELAPSED OVARIAN CANCER
Nicoletta Colombo (Italy)
18:40 TRANSLATING CLINICAL TRIALS INTO CLINICAL PRACTICE
Mansoor Mirza (Denmark)
19:00 IDENTIFYING SUITABLE PATIENTS FOR PARP INHIBITOR THERAPY IN OVARIAN CANCER: TODAY AND THE FUTURE
Susana Banerjee (UK)
19:20 PANEL/AUDIENCE Q&A
19:40 SUMMARY AND CLOSE
Sunday, October 30, 2016
13:00 – 14:00
3B
MEET THE ROBOTIC PROFESSORS
Symposium Organized by: Intuitive Surgical
13:00 FROM OPEN TO ROBOTOC SURGERY
Angelo Maggioni, Italy
13:30 FROM LAPAROSCOPIC TO ROBOTIC SURGERY
Fabrice Lecuru, France
13:30 – 15:00
AUD I
MANAGING RELAPSED OVARIAN CANCER IN A RAPIDLY EVOLVING LANDSCAPE
Symposium Organized by: Pharmarmar
Chair: Andrés Poveda,Spain and Christian Marth (Austria)
13:30 WELCOME AND INTRODUCTION (CHRISTIAN MARTH)
Christian Marth, Austria
13:35 UPDATE ON RELAPSED OVARIAN CANCER TREATMENT, FROM NEW CONSENSUS TO DAILY CLINICAL PRACTICE
Antonio González, Spain
13:55 DEBATE: PLATINUM OR NON-PLATINUM, THAT IS THE QUESTION
Moderated by: Andrés Poveda,Spain and Christian Marth, Austria
14:15 TRABECTEDIN MOA AND PLATINUM RESISTANCE: MOLECULAR RATIONALE
Isabelle Ray-Coquard, France
14:30 WHEN NON-PLATINUM IS THE ANSWER: THE ROLE OF TRABECTEDIN+PLD
Nicoletta Colombo, Italy
14:50 QUESTIONS AND CLOSING
Andrés Poveda,Spain
Monday October 31st, 2016
8:00 – 9:00
AUD III + IV
HE4 BIOMARKER ADOPTION: CURRENT AND FUTURE APPLICATIONS
Symposium Organized by: Fujirebio Diagnostics
Chair: Christianne Lok (The Netherlands)
08:00 ADDED VALUE OF HE4 SERUM MARKER IN OVARIAN CANCER PATIENTS
Sharon O'Toole AND Noreen Gleeson (Ireland)
08:30 IMPROVING TRIAGE AND CARE IN GYNECOLOGICAL CANCER (ENDOMETRIAL AND OVARIAN): ROLE OF HE4 BIOMARKER
Christianne Lok (The Netherlands)
